Lotte Biologics to raise 255.3B KRW for facility
롯데지주
004990
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2473
Risk-adjusted indicator based on 2473 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Common Shares: 4,209,000 Shares
- • Issuance Price per Share: 60,658 KRW
- • Total Funding for Facilities: 255,309,522,000 KRW (approx. 255.3B KRW)
- • Pre-Dilution Shares: 18,292,169 Shares
- • Subsidiary's Total Assets: 1,979,933,424,978 KRW (approx. 1.98T KRW)
AI Analysis Summary
Lotte Corporation's subsidiary, LOTTE BIOLOGICS Co., Ltd., has decided on a paid-in capital increase to raise 255.3 billion KRW for facility investments, specifically for the Songdo Bio Campus Plant 1 construction. The issuance involves 4,209,000 new common shares at 60,658 KRW per share, representing a potential dilution of approximately 23.0% (4,209,000 new shares / 18,292,169 pre-increase shares). The funds are solely for facility expansion, indicating long-term growth potential for the subsidiary. However, the dilution could impact existing shareholder value. Unsubscribed shares will be unissued.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.